{"title":"Vitamin D receptor activator-associated calcium-alkali syndrome-like phenotype without calcium supplementation: a case series of seven patients.","authors":"Takuya Kumagai, Tsuyoshi Ono","doi":"10.1007/s13730-026-01207-1","DOIUrl":null,"url":null,"abstract":"<p><p>Vitamin D receptor activators (VDRAs) are widely prescribed for osteoporosis and CKD-mineral and bone disorder in Japan. Although hypercalcemia and acute kidney injury (AKI) are recognized adverse effects, metabolic alkalosis in these patients has received limited attention as a feature of calcium-alkali syndrome (CAS).We retrospectively reviewed patients with VDRA-associated hypercalcemia at our institution between April 2016 and June 2026, applying study-defined operational criteria for a CAS-like phenotype: hypercalcemia, elevated bicarbonate compatible with a metabolic alkalosis component (HCO₃⁻ ≥ 26 mmol/L), and AKI (KDIGO criteria). Seven elderly women fulfilled all criteria. Six received eldecalcitol (0.75 μg/day) and one received alfacalcidol (1.0 μg/day). Underlying CKD was present in six patients.Time from initiation to onset ranged from 1 to 120 months (median 18 months). Three cases had no identified exogenous alkali source. The serum Na-Cl difference was elevated in all patients (range 36-53 mEq/L). Renal outcomes were complete recovery in three patients, partial recovery in two, and non-recovery in one; one patient died of worsening heart failure.VDRA-associated hypercalcemia can present as a CAS-like phenotype even without calcium supplementation, and renal outcomes may be irreversible. Because the temporal relationship between hypercalcemia and metabolic alkalosis cannot be established from these retrospective data, the main clinical message is that elderly patients receiving VDRAs, particularly those with CKD or relevant concomitant medications, require periodic calcium monitoring and prompt evaluation when nonspecific symptoms, AKI, or an elevated Na-Cl difference are observed.</p>","PeriodicalId":9697,"journal":{"name":"CEN Case Reports","volume":"15 6","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13740417/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CEN Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13730-026-01207-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Vitamin D receptor activators (VDRAs) are widely prescribed for osteoporosis and CKD-mineral and bone disorder in Japan. Although hypercalcemia and acute kidney injury (AKI) are recognized adverse effects, metabolic alkalosis in these patients has received limited attention as a feature of calcium-alkali syndrome (CAS).We retrospectively reviewed patients with VDRA-associated hypercalcemia at our institution between April 2016 and June 2026, applying study-defined operational criteria for a CAS-like phenotype: hypercalcemia, elevated bicarbonate compatible with a metabolic alkalosis component (HCO₃⁻ ≥ 26 mmol/L), and AKI (KDIGO criteria). Seven elderly women fulfilled all criteria. Six received eldecalcitol (0.75 μg/day) and one received alfacalcidol (1.0 μg/day). Underlying CKD was present in six patients.Time from initiation to onset ranged from 1 to 120 months (median 18 months). Three cases had no identified exogenous alkali source. The serum Na-Cl difference was elevated in all patients (range 36-53 mEq/L). Renal outcomes were complete recovery in three patients, partial recovery in two, and non-recovery in one; one patient died of worsening heart failure.VDRA-associated hypercalcemia can present as a CAS-like phenotype even without calcium supplementation, and renal outcomes may be irreversible. Because the temporal relationship between hypercalcemia and metabolic alkalosis cannot be established from these retrospective data, the main clinical message is that elderly patients receiving VDRAs, particularly those with CKD or relevant concomitant medications, require periodic calcium monitoring and prompt evaluation when nonspecific symptoms, AKI, or an elevated Na-Cl difference are observed.
期刊介绍:
Clinical and Experimental Nephrology (CEN) Case Reports is a peer-reviewed online-only journal, officially published biannually by the Japanese Society of Nephrology (JSN). The journal publishes original case reports in nephrology and related areas. The purpose of CEN Case Reports is to provide clinicians and researchers with a forum in which to disseminate their personal experience to a wide readership and to review interesting cases encountered by colleagues all over the world, from whom contributions are welcomed.